Free Trial

Cantor Fitzgerald Predicts ZVRA FY2025 Earnings

Zevra Therapeutics logo with Medical background

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zevra Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will post earnings per share of $1.88 for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share.

A number of other equities research analysts also recently weighed in on the company. Guggenheim assumed coverage on Zevra Therapeutics in a research note on Monday, October 7th. They set a "buy" rating and a $20.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Canaccord Genuity Group cut their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $21.57.

Check Out Our Latest Report on Zevra Therapeutics

Zevra Therapeutics Stock Up 0.1 %

NASDAQ ZVRA traded up $0.01 during trading on Thursday, reaching $8.11. 138,352 shares of the company's stock were exchanged, compared to its average volume of 386,177. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The company's fifty day simple moving average is $8.66 and its 200-day simple moving average is $7.83. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market capitalization of $432.91 million, a PE ratio of -4.12 and a beta of 2.01.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the business earned ($0.40) EPS.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in Zevra Therapeutics in the fourth quarter worth $94,000. SG Americas Securities LLC raised its position in shares of Zevra Therapeutics by 54.6% during the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock worth $196,000 after acquiring an additional 8,302 shares during the last quarter. Virtu Financial LLC bought a new stake in Zevra Therapeutics in the third quarter valued at about $127,000. Barclays PLC increased its holdings in Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company's stock valued at $399,000 after purchasing an additional 42,926 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company's stock valued at $7,246,000 after purchasing an additional 129,600 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company's stock.

Zevra Therapeutics Company Profile

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

Featured Stories

Earnings History and Estimates for Zevra Therapeutics (NASDAQ:ZVRA)

Should You Invest $1,000 in Zevra Therapeutics Right Now?

Before you consider Zevra Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.

While Zevra Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines